Adial Pharmaceuticals, Inc.
ADIL
$0.3721
$0.00010.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.06M | 5.18M | 5.06M | 5.36M | 5.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.30M | 8.71M | 8.28M | 8.13M | 7.27M |
| Operating Income | -8.30M | -8.71M | -8.28M | -8.13M | -7.27M |
| Income Before Tax | -8.45M | -8.95M | -13.20M | -13.03M | -12.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.45 | -8.95 | -13.20 | -13.03 | -12.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -15.90K | -53.20K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.45M | -8.95M | -13.20M | -13.05M | -12.24M |
| EBIT | -8.30M | -8.71M | -8.28M | -8.13M | -7.27M |
| EBITDA | -8.30M | -8.71M | -8.28M | -8.13M | -7.27M |
| EPS Basic | -1.22 | -1.63 | -3.48 | -3.98 | -4.78 |
| Normalized Basic EPS | -1.24 | -1.49 | -2.65 | -2.48 | -2.96 |
| EPS Diluted | -1.22 | -1.63 | -3.48 | -3.98 | -4.78 |
| Normalized Diluted EPS | -1.24 | -1.49 | -2.65 | -2.48 | -2.96 |
| Average Basic Shares Outstanding | 29.41M | 22.97M | 19.39M | 15.31M | 10.65M |
| Average Diluted Shares Outstanding | 29.41M | 22.97M | 19.39M | 15.31M | 10.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |